China FDA Prepares to Review Evomela for Approval in Multiple Myeloma Treatment
Multiple myeloma patients in China may soon have…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Multiple Myeloma Research Foundation Awards $7 Million to Accelerate Precision Immunotherapies for Myeloma Patients
As part of its $15 million Immunotherapy Initiative, the…
Xgeva Gains Europe’s Approval for Preventing Bone Lesions in Multiple Myeloma
The European Commission has extended Xgeva‘s (denosumab) approval…
Revlimid, Dexamethasone Combo Shows Benefits for Multiple Myeloma in Real-world Study
The combination of Revlimid (lenalidomide) and dexamethasone for the treatment…
Bluebird Bio and Celgene Partner to Advance bb2121, Potential Multiple Myeloma CAR T-cell Therapy
The investigational therapy bb2121, a possible treatment for…
ACCoRd Trial to Test Ninlaro Treatment for ASCT-Relapsed Multiple Myeloma
A new Phase 3 clinical trial called ACCoRd is…
